 new management confirmed the process ‘remains pending’. ){kind=link}
The frozen US cannabis rescheduling process appears to be stuck in limbo for the foreseeable future, as the Drug Enforcement Administration’s (DEA’s) new management confirmed the process ‘remains pending’.
In a joint report to DEA Administrative Law Judge (ALJ) John Mulrooney earlier this week, DEA representatives said that no progress has been made six months after it was ‘temporarily’ suspended amid an interlocutory appeal.
The DEA, which is required to give an annual progress report, issued a similar statement to that in April. They stated that Derek Maltz, then the Acting Administrator, had not yet set up a meeting schedule to allow the parties to present their arguments on whether they should continue to act as the promoter of the new rule.
On Monday, a further notice stated that the ‘interlocutory appeal to the Acting Administrator regarding their Motion to Reconsider remains pending with the Acting Administrator’, and that no briefing schedule has been set’.
There has been another major change of leadership at the DEA since the May departure of Derek Maltz. However, this has largely slipped under the radar.
Maltz has been replaced by Robert Murphy as Deputy Director, a man who was a fierce opponent of cannabis. However, the DEA still hasn’t made any official announcements about their leadership changes.
Cannabis advocates are hiding the dangerous truth they don’t wish you to learn.
A major review suggests that cannabis use increases the risk of heart attack and stroke more than cocaine or other drugs.
Let’s not forget about the Chinese criminal networks that are running grow operations all over the…
— Derek Maltz Sr (@derekmaltz_sr) July 1, 2025
This transition appears to have been kept quiet by the DEA, with Maltz announcing his departure on his personal LinkedIn profile, but numerous sources continuing to cite him as acting administrator, and the ‘DEA Leadership’ tab on the administration’s official website inaccessible.
Murphy’s captaincy is unlikely to last long. Trump has nominated Terrance Cole for the position, and he must be confirmed.
During a confirmation hearing in May, he informed lawmakers that reviewing the stalled process would be ‘one of my first priorities’ if confirmed. But the law enforcement officer did not endorsing reclassification as proposed, saying that it was necessary to further study the topic.
Cole acknowledged delays in the DEA’s ongoing review of cannabis’s status under federal law, stating that he was ‘not familiar exactly where we are, but I know the process has been delayed numerous times, and it’s time to move forward.’
When pressed by Sen. Alex Padilla, a Democrat from California, as to whether he would commit to seeing the process through, he declined to offer a concrete position, stating only that he ‘need(s) to understand more where the agencies are, and look at the science behind it,” he said, adding that he wanted to ‘listen to the experts’ before making a determination.
The frozen US cannabis rescheduling process appears to be stuck in limbo for the foreseeable future, as the Drug Enforcement Administration’s (DEA’s) new management confirmed the process ‘remains pending’.
In a joint report to DEA Administrative Law Judge (ALJ) John Mulrooney earlier this week, DEA representatives said that no progress has been made six months after it was ‘temporarily’ suspended amid an interlocutory appeal.
The DEA, which is required to give an annual progress report, issued a similar statement to that in April. They stated that Derek Maltz, then the Acting Administrator, had not yet set up a meeting schedule to allow the parties to present their arguments on whether they should continue to act as the promoter of the new rule.
On Monday, a further notice stated that the ‘interlocutory appeal to the Acting Administrator regarding their Motion to Reconsider remains pending with the Acting Administrator’, and that no briefing schedule has been set’.
The DEA also experienced another leadership transition following Derek Maltz’s resignation in May. However, this change has largely been under-reported.
Maltz is a strong anti-cannabis activist. It is believed that Deputy Administrator Robert Murphy has succeeded him, although the DEA is yet to make an official announcement about its new leadership.
Cannabis advocates are hiding the dangerous truth they don’t wish you to learn.
A major review suggests that cannabis use increases the risk of heart attack and stroke more than cocaine or other drugs.
Let’s not forget about the Chinese criminal networks that are running grow operations all over the…
— Derek Maltz Sr (@derekmaltz_sr) July 1, 2025
This transition appears to have been kept quiet by the DEA, with Maltz announcing his departure on his personal LinkedIn profile, but numerous sources continuing to cite him as acting administrator, and the ‘DEA Leadership’ tab on the administration’s official website inaccessible.
Murphy’s captaincy is unlikely to last long. Trump has nominated Terrance Cole for the position, and he must be confirmed.
During a confirmation hearing in May, he informed lawmakers that reviewing the stalled process would be ‘one of my first priorities’ if confirmed. But the law enforcement officer did not endorsing reclassification as proposed, saying that it was necessary to further study the topic.
Cole acknowledged delays in the DEA’s ongoing review of cannabis’s status under federal law, stating that he was ‘not familiar exactly where we are, but I know the process has been delayed numerous times, and it’s time to move forward.’
When pressed by Sen. Alex Padilla, a Democrat from California, as to whether he would commit to seeing the process through, he declined to offer a concrete position, stating only that he ‘need(s) to understand more where the agencies are, and look at the science behind it,” he said, adding that he wanted to ‘listen to the experts’ before making a determination.
Cannabis Law Resources for Poland
Browse essential legal pages on cannabis sales and cultivation in Poland. You can use these resources to learn about the requirements for certification, permissions and compliance.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland